Clinical-pharmacokinetic investigations of acetylsalicylic acid in cases of imminent premature delivery.
The pharmacokinetics of acetylsalicylic acid have been examined in a dose of 3.6 g per day (0.9 g every 6 h) for 4 days, and the effect of the drug in 25 gravidae, threatened by premature delivery, has also been studied. Salicylate in maternal blood was higher than in amniotic fluid, umbilical cord and foetus at birth. It is concluded that 9 h after a dose of 3.6 g acetylsalicylic acid, the salicylate level in maternal blood was sufficient to reduce the number of uterine spasms in most patients. No effect of the drug on blood coagulation in mother or child was observed.
D000653:Amniotic Fluid / Q000378:metabolism; D001241:Aspirin / Q000378:metabolism* / Q000627:therapeutic use; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007700:Kinetics; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D012459:Salicylates / Q000652:urine; D020156:Salicylic Acid; D013997:Time Factors
D012459:Salicylates; D020156:Salicylic Acid; D001241:Aspirin